When to Adjust the Protocol Signs it is working (stay the course): Gradual, steady weight loss of 0.5-1.5 lbs per week after reaching maintenance dose Reduced appetite and food cravings Improving fasting glucose, HbA1c, or lipid panels on bloodwork Manageable or no GI side effects Signs to discuss changes with your provider: No weight change after 8+ weeks at maintenance dose
Due to our partnership with a FDA approved compounding pharmacy, we are confident in the product we are prescribing.
Clinical trials found that many semaglutide users achieve results comparable to surgical patients without the permanent anatomical changes or associated risks
Finan B, Muller TD, Clemmensen C, Perez-Tilve D, DiMarchi RD, Tschop MH
Principal Investigator, Linus Pauling Institute Professor, College of Public Health and Human Sciences Endowed Director, Moore Family Center for Whole Grain Foods, Nutrition and Preventive Health Oregon State University Copyright 2005-2026 Linus Pauling Institute Figure Alternative Text Figure 1
WEDNESDAY, June 10, 2026 (HealthDay News) -- For adults with type 2 diabetes (T2D) that is inadequately controlled with diet and exercise alone, retatrutide, a triple hormone receptor agonist, is associated with significant improvements in glycemic control and body weight reductions, according to a study published online June 6 in The Lancet to coincide with the annual meeting of the American Diabetes Association, held from June 5 to 8 in New Orleans.Harpreet S
